Hinge Health Closing Valuation Gap

The rebound shows that public investors are starting to treat Hinge Health less like a pandemic era digital health bet and more like a scaled care delivery business with real revenue. After listing in May 2025 at an initial market cap near $3B, the stock moved high enough by May 2026 to lift equity value to about $4.3B, still below the $6.2B private peak from the 2021 Series E but clearly closing the gap as growth and public market credibility improved.1 2 3 4 5

• The reset from private to public was large. Hinge priced 13.666M IPO shares at $32 on May 21, 2025, then began trading on May 22, 2025. That public entry point sat far below the 2021 private round that valued the company at $6.2B.1 2 4
• The recovery has been supported by operating scale, not just market mood. Internal company data shows revenue rising from about $293M in 2023 to about $390M in 2024, or roughly 33 percent growth, which helps explain why investors were willing to re rate the stock after IPO.3
• The market context matters. Hinge sells digital MSK care, meaning employers and health plans pay for an app, care team, and motion guided exercise workflow that aims to reduce surgery, imaging, and physical therapy spend. That is closer to a measurable medical cost savings product than a general wellness app, which supports higher valuation durability.3 5 6

The next leg of valuation recovery depends on Hinge proving it can keep compounding revenue while defending its edge as MSK care gets more crowded. If it keeps turning a focused pain treatment workflow into a broader employer and payer cost control product, the public market can continue pulling its valuation toward and potentially past the old private peak.3 5 6